CN111686087A - 含ndma杂质低的盐酸雷尼替丁片的制备方法 - Google Patents
含ndma杂质低的盐酸雷尼替丁片的制备方法 Download PDFInfo
- Publication number
- CN111686087A CN111686087A CN202010731924.4A CN202010731924A CN111686087A CN 111686087 A CN111686087 A CN 111686087A CN 202010731924 A CN202010731924 A CN 202010731924A CN 111686087 A CN111686087 A CN 111686087A
- Authority
- CN
- China
- Prior art keywords
- ranitidine hydrochloride
- ndma
- coating
- impurities
- containing low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229960001520 ranitidine hydrochloride Drugs 0.000 title claims abstract description 58
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000012535 impurity Substances 0.000 title claims abstract description 21
- 229940102838 methylmethacrylate Drugs 0.000 title description 2
- 238000000576 coating method Methods 0.000 claims abstract description 48
- 239000011248 coating agent Substances 0.000 claims abstract description 46
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 5
- 238000003825 pressing Methods 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000007888 film coating Substances 0.000 abstract description 4
- 238000009501 film coating Methods 0.000 abstract description 4
- 229940057948 magnesium stearate Drugs 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000007907 direct compression Methods 0.000 abstract 1
- 239000011812 mixed powder Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 41
- VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 16
- 229940108322 zantac Drugs 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 4
- 238000009475 tablet pressing Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960000620 ranitidine Drugs 0.000 description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- ZLSWBLPERHFHIS-UHFFFAOYSA-N Fenoprop Chemical compound OC(=O)C(C)OC1=CC(Cl)=C(Cl)C=C1Cl ZLSWBLPERHFHIS-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010731924.4A CN111686087A (zh) | 2020-07-27 | 2020-07-27 | 含ndma杂质低的盐酸雷尼替丁片的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010731924.4A CN111686087A (zh) | 2020-07-27 | 2020-07-27 | 含ndma杂质低的盐酸雷尼替丁片的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111686087A true CN111686087A (zh) | 2020-09-22 |
Family
ID=72486798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010731924.4A Pending CN111686087A (zh) | 2020-07-27 | 2020-07-27 | 含ndma杂质低的盐酸雷尼替丁片的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111686087A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112526005A (zh) * | 2020-10-14 | 2021-03-19 | 江苏汉斯通药业有限公司 | 雷尼替丁类药物中亚硝胺类物质的高效液相色谱分析方法 |
WO2021259396A2 (zh) | 2021-08-20 | 2021-12-30 | 威智医药有限公司 | 一种亚硝胺杂质、能够减少亚硝胺杂质生成的伐尼克兰药物组合物及其制备与应用 |
CN114591274A (zh) * | 2022-03-09 | 2022-06-07 | 河北海力香料股份有限公司 | 一种盐酸雷尼替丁的制备方法 |
WO2022117771A1 (en) * | 2020-12-04 | 2022-06-09 | Opella Healthcare Group Sas | Composition containing ranitidine having a low iron content |
CN114839288A (zh) * | 2022-04-27 | 2022-08-02 | 湖南省药品检验检测研究院 | 一种盐酸雷尼替丁样品的前处理方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880636A (en) * | 1988-05-13 | 1989-11-14 | Franz Robert M | Film coated tablet of ranitidine HCl |
CN101032479A (zh) * | 2007-04-29 | 2007-09-12 | 丽珠医药集团股份有限公司 | 一种治疗胃肠道溃疡的药物及其制备方法 |
CN109700775A (zh) * | 2019-03-14 | 2019-05-03 | 瑞阳制药有限公司 | 盐酸雷尼替丁片的制备方法 |
-
2020
- 2020-07-27 CN CN202010731924.4A patent/CN111686087A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880636A (en) * | 1988-05-13 | 1989-11-14 | Franz Robert M | Film coated tablet of ranitidine HCl |
CN101032479A (zh) * | 2007-04-29 | 2007-09-12 | 丽珠医药集团股份有限公司 | 一种治疗胃肠道溃疡的药物及其制备方法 |
CN109700775A (zh) * | 2019-03-14 | 2019-05-03 | 瑞阳制药有限公司 | 盐酸雷尼替丁片的制备方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112526005A (zh) * | 2020-10-14 | 2021-03-19 | 江苏汉斯通药业有限公司 | 雷尼替丁类药物中亚硝胺类物质的高效液相色谱分析方法 |
WO2022117771A1 (en) * | 2020-12-04 | 2022-06-09 | Opella Healthcare Group Sas | Composition containing ranitidine having a low iron content |
WO2021259396A2 (zh) | 2021-08-20 | 2021-12-30 | 威智医药有限公司 | 一种亚硝胺杂质、能够减少亚硝胺杂质生成的伐尼克兰药物组合物及其制备与应用 |
CN114591274A (zh) * | 2022-03-09 | 2022-06-07 | 河北海力香料股份有限公司 | 一种盐酸雷尼替丁的制备方法 |
CN114591274B (zh) * | 2022-03-09 | 2024-05-24 | 石家庄海力药业有限公司 | 一种盐酸雷尼替丁的制备方法 |
CN114839288A (zh) * | 2022-04-27 | 2022-08-02 | 湖南省药品检验检测研究院 | 一种盐酸雷尼替丁样品的前处理方法 |
CN114839288B (zh) * | 2022-04-27 | 2023-11-07 | 湖南省药品检验检测研究院 | 一种盐酸雷尼替丁样品的前处理方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111686087A (zh) | 含ndma杂质低的盐酸雷尼替丁片的制备方法 | |
CN110538153B (zh) | 一种高稳定性、快速释放的固体制剂及其制备方法 | |
CN112494440B (zh) | 一种磷酸西格列汀片及其制备方法 | |
CN106265641B (zh) | 一种含有维格列汀和二甲双胍的药物组合物及其制备方法 | |
WO2018177317A1 (zh) | 一种盐酸二甲双胍缓释片制备方法 | |
CN100438917C (zh) | 一种微晶纤维素乳糖的制备方法 | |
CN106924237B (zh) | 一种含有恩格列净和盐酸二甲双胍的药物组合物 | |
WO2021143513A1 (zh) | 肠溶包衣材料及其制备方法和肠溶制品 | |
CN109010298B (zh) | 一种二甲双胍格列吡嗪复方组合物及其制备方法 | |
CN103142531A (zh) | 一种阿司匹林缓释片及其制备方法 | |
CN113181129A (zh) | 一种稳定的硫辛酸片的制备方法 | |
CN113679684B (zh) | 磷酸西格列汀组合物、磷酸西格列汀片及其制备方法和用途 | |
CN105012961B (zh) | 稳定的药物组合物及其制备方法 | |
CN112826806A (zh) | 一种缬沙坦片制备方法和缬沙坦片 | |
CN113069428B (zh) | 一种雷贝拉唑钠肠溶片的制备方法 | |
CN112641743A (zh) | 一种用于治疗高血压的复方制剂及其制备工艺 | |
CN111643470A (zh) | 罗氟司特薄膜包衣片制备工艺 | |
CN111110647A (zh) | 含盐酸考来维仑的药物组合物及其制备方法 | |
CN110876728A (zh) | 盐酸二甲双胍速释制剂的制备方法 | |
CN103143025A (zh) | 一种水性肠溶包衣粉及其制备及使用方法 | |
CN112933060B (zh) | 一种吡拉西坦片及其制备方法 | |
CN109157519A (zh) | 一种氧氟沙星片剂的制备方法 | |
CN117338740B (zh) | 一种沙格列汀二甲双胍缓释片及其制备方法 | |
CN103638046B (zh) | 一种氯芬黄敏片及制备方法 | |
CN101664556B (zh) | 一种乳糖-聚维酮-交联聚维酮预混剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 256100 Ruiyang Road, Yiyuan County, Zibo City, Shandong Province Applicant after: Ruiyang Pharmaceutical Co.,Ltd. Applicant after: SHANDONG HI-QUAL PHARMATECH CO.,LTD. Address before: 256100 Ruiyang Road, Yiyuan County, Zibo City, Shandong Province Applicant before: REYOUNG PHARMACEUTICAL Co.,Ltd. Applicant before: SHANDONG HI-QUAL PHARMATECH Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Miao Dezu Inventor after: Huang Jingshan Inventor after: Li Wei Inventor after: Chen Deren Inventor after: He Dunwei Inventor before: Miao Dezu Inventor before: Huang Jingshan Inventor before: Chen Deren |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200922 |